TREATMENT PATTERN AND COST-EFFECTIVENESS ANALYSIS OF ORAL HYPOGLYCEMICS FOR TYPE 2 DIABETES MELLITUS OUTPATIENTS AT REGIONAL GENERAL HOSPITAL, INDONESIA

  • Yusmaniar Jakarta II Health Polytechnic of the Ministry of Health, Jakarta, Indonesia
  • Adin Hakim Kurniawan Jakarta II Health Polytechnic of the Ministry of Health, Jakarta, Indonesia
  • Surahman Jakarta II Health Polytechnic of the Ministry of Health, Jakarta, Indonesia
  • Muhammad Naufal Fauzan Jakarta II Health Polytechnic of the Ministry of Health, Jakarta, Indonesia
Keywords: Oral Antidiabetic, Cost-Effectiveness Analysis, OutPatient

Abstract

Type 2 diabetes mellitus (DM) has become a major problem, with most cases appearing as a degenerative disease that is almost uncontrollable using single or combined oral therapy. Therefore, this study aims to examine the sociodemographics, treatment pattern, and cost-effectiveness analysis of oral hypoglycemics for type 2 DM outpatients at Cempaka Putih Regional General Hospital, Central Jakarta, Indonesia. This descriptive study was conducted within six months using a cross sectional design. The inclusion criteria were 18 years old type 2 DM patients receiving outpatient treatment, patients with a primary diagnosis of type 2 DM without complications, health insurance (BPJS), good medical records, and the pharmacoeconomic values approach with the Cost-Effectiveness Analysis (CEA) method, which is a review from hospital and healthcare perspective. A total of 79 patients participated and the analysis was carried out using ACER and ICER calculations of cost-effective therapy in each group. The results showed that the most cost-effective therapy for the oral group is a biguanide with metformin 500 mg and an ACER value of IDR19,196, 2 combination therapies namely Glibenclamide and metformin with ACER of IDR39,160, and the 3 combinations of metformin + glimepiride + acarbose IDR156,761. The lowest calculation of ICER value was between monotherapy metformin IDR16,896 and oral combination of metformin + glibenclamide IDR19,883. This indicated that pharmacoeconomic data allow users to make more rational decisions in selecting therapy, treatment, as well as clinical and administrative decision-makers, including physicians, pharmacists, formulary committee members, and administrators for insurance companies.

References

Agarwal A, Jadhav P, Deshmukh Y. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014;

Bagle TR, Vare VA, Nimgade A, Hire RC, Sharma Y, Kshirsagar P. Pharmacoeconomic evaluation in cost of illness in type 2 diabetes mellitus patients in a tertiary care hospital. Int J Basic Clin Pharmacol. 2017 Sep 23;6(10):2334.

Sharma A. A Cross-Sectional Study on Diabetes Mellitus Type-2 at a Tertiary Care Hospital. Adv Res Gastroenterol Hepatol. 2017 Nov 21;8(1).

Risso T, Furtado C. Rational use of blood glucose test strips for self-monitoring in patients with diabetes mellitus: Economic impact in the Portuguese healthcare system. Diabetes Res Clin Pract. 2017 Dec;134:161–7.

Ramadhan IR, Syurya W, Dharma T. ANALYSIS OF THE EFFECTIVENESS OF MONOTHERAPY ANTIDIABETIC MEDICINE AND COMBINATION IN DIABETES MELITUS PATIENT II TYPE II PARTICIPANTS OF BPJS PATIENTS IN HOSPITAL IN ISLAMIC CEMPAKA PUTIH. 2020;5(1):34–47.

Gupta H, Gupta S, Mahajan V, Bhat NK, Kotwal SK. Prescribing Pattern of Drugs in Outdoor Patients with Type 2 Diabetes Mellitus in Relation to the Duration of Diabetes in a Tertiary Care Teaching Hospital – A Prospective Observational Study. J Evid Based Med Healthc. 2021 Feb 1;8(05):256–60.

MUSSTTAF GS, HABIB A, MAHTOOK M. DRUG PRESCRIBING PATTERN AND COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: REAL-WORLD DATA FROM INDIAN PUBLICATION. Asian J Pharm Clin Res. 2021 May 14;45–9.

Mori AT, Robberstad B. Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: A systematic review. Vol. 12, BMC Medical Informatics and Decision Making. 2012.

Johny SA, Anupriya AP, John O, Surekha G, Paarakh PM. Evaluation of pharmacoeconomics, medication adherence and quality of life in type 2 diabetes mellitus patients. Int J Res Pharm Sci. 2017;8(3).

Ngalesoni FN, Ruhago GM, Mori AT, Robberstad B, Norheim OF. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Serv Res. 2016 Dec 17;16(1):185.

Saroj Dhakal, Shrijana Shakya, Shree Krishna Sharma. Cost-Effectiveness Analysis of Oral Hypoglycemics for Type-2 Diabetes Mellitus at a Tertiary Care Hospital, Nepal. J Pharm Pharmacol. 2019 Oct 8;7(10).

Zhai S, Georgy A, Liang Z, Zhi J. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients. Clin Pharmacol Drug Dev. 2016;5(6).

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care. 2015 Jul;3(1):e000093.

Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs in Context. 2018.

Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, et al. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force. Indian J Endocrinol Metab. 2018;22(1):132–57.

Davitt CC, Hersh AR, Packer CH, Munn A, Vinson A, Caughey AB. 713: Oral hypoglycemic agents in the treatment of gestational diabetes mellitus: a cost-effectiveness analysis. Am J Obstet Gynecol. 2020;222(1).

C. DDL-C, M. A-M, J. K-J, R. C-E, J.M. M-N. Cost-effectiveness study of oral hypoglycemic agents in outpatients diagnosed with type-2 diabetes attending a primary care public clinic in Mexico City. Value Heal. 2011;14(7).

Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Vol. 12, Therapeutic Advances in Endocrinology and Metabolism. 2021.

Wasiq AW, Fazli N, Ahadi AN, Amirzada MZ, Hayat MS, Ishaq N, et al. Prevalence of Type 2 Diabetes Mellitus and Its Association With Socioeconomic Status in Kandahar City: a Cross-Sectional Study. Malaysian J Public Heal Med. 2021;21(3):26–35.

Rubio CR, Centellas JM, Bueno MRM, Fernandez CF, Gonzalez DM, Grande DB, et al. Metformine and severe lactic acidosis. Nephrol Dial Transplant. 2017;32.

Andayani TM, Ibrahim MI, Asdie A. Pengaruh kombinasi terapi sulfonilurea, metformin, dan acarbose pada pasien diabetes mellitus tipe 2. Maj Farm Indones. 2009;20(4).

Swetha NK. Comparison of fasting blood glucose & post prandial blood glucose with HbA1c in assessing the glycemic control. Int J Healthc Biomed Res. 2014;(2):134.

Published
2022-08-20
How to Cite
Yusmaniar, Kurniawan, A. H., Surahman, & Fauzan, M. N. (2022). TREATMENT PATTERN AND COST-EFFECTIVENESS ANALYSIS OF ORAL HYPOGLYCEMICS FOR TYPE 2 DIABETES MELLITUS OUTPATIENTS AT REGIONAL GENERAL HOSPITAL, INDONESIA. Malaysian Journal of Public Health Medicine, 22(2), 27-34. Retrieved from http://mjphm.org/index.php/mjphm/article/view/1615
Section
Articles